Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Buys DuPont: Re-Enters Imaging Agents, Adds To HIV Line

Executive Summary

Bristol-Myers Squibb will re-enter the radiopharmaceutical business via the acquisition of DuPont Pharma.

You may also be interested in...



Deals Of The Week Untangles The String Of Pearls

In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.

Bristol Decreasing Reliance On Third-Party R&D, Focusing On In-House Efforts

Bristol-Myers Squibb will decrease its dependence on externally sourced development compounds as it ramps up an internal R&D effort, Chief Scientific Officer Peter Ringrose, PhD, said during a Nov. 7 investor update in New York City

Bristol Decreasing Reliance On Third-Party R&D, Focusing On In-House Efforts

Bristol-Myers Squibb will decrease its dependence on externally sourced development compounds as it ramps up an internal R&D effort, Chief Scientific Officer Peter Ringrose, PhD, said during a Nov. 7 investor update in New York City

Related Content

UsernamePublicRestriction

Register

PS037975

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel